Can osilodrostat be used indefinitely in poor surgical candidates with cushing syndrome from adrenal adenoma?

Community
Company
News
Contact Us
Sign in

Topics: Endocrinology • Adrenal Disorders

Answer from: at Community Practice

There is no restriction on the duration of therapy with osilodrostat. One of the goals is to improve the clinical condition of the patient, so the patient can become a surgical candidate.

18210

Related Questions

What is your approach to differentiating pseudo-Cushing's state from Cushing's syndrome?

What is the next best anti-hypertensive medication to start after mineralocorticoid receptor antagonists in patients with primary aldosteronism?

In patients with hypertension and suspected primary aldosteronism who have undergone negative confirmatory testing, what follow-up and monitoring strategies would you recommend to ensure early detection of potential aldosteronism?

What further work-up (if any) should be considered in patients with pituitary microadenoma and stigmata of Cushing's disease but low ACTH and repeatedly normal plasma, urinary, and salivary cortisol levels?

Is there an indication for adrenalectomy in patients with subclinical Cushing syndrome and adrenal nodule?

How do you personalize glucocorticoid dosing for patients with adrenal insufficiency during non-standard stress events, such as unexpected major life changes or unusual physical exertion?

Is a significant rise in cortisol post cosyntropin stimulation sufficient to rule out adrenal insufficiency in patients with low albumin?

Under what circumstances would you refer a patient with mild autonomous cortisol secretion without features of Cushing syndrome for adrenalectomy?

In adult women with NCCAH, is there a benefit in using supratherapeutic doses of prednisone in addition to clomiphene to improve fertility rates?

Should a short trial of androgen therapy be used in patients with primary adrenal insufficiency suffering from persistent fatigue and hypoactive sexual desire despite sufficient glucocorticoid and mineralocorticoid replacement?